Please refer the attached intimation.

November 06, 2026 Listing Compliance Department BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai — 400 001. REF: SCRIP CODE: 500422 ISIN: INE019B01010 Dear Sir/ Madam, Subject: Newspaper advertisement of Un-audited (Standalone and Consolidated) Financial Results of the Company for the Quarter and Half-year Ended September 30, 2026, pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Further to the Outcome of Board Meeting submitted on November 04, 2026 under Regulation 30 and 33 of the SEBI Listing Regulations and in compliance with Regulation 47 of the SEBI Listing Regulations, we are enclosing herewith copies of newspaper advertisement published in Financial Express (English) and Mumbai Lakshadeep (Marathi) containing Un-audited (Standalone and Consolidated) Financial Results of the Company for the quarter and half-year ended September 30, 2026 (“Un-audited Financial Results”), Quick Response code and the details of webpage wherein the Un-audited Financial Results are accessible. The above information is also available on the Company’s website at www.transchem.net Kindly take the same on your records. Thanking You, Yours Faithfully, For Transchem Limited Neeraja Karandikar Company Secretary ACS: 10130 Encl: a/a CIN: L66120MH1976PLC019327 Registered Office: 111, Maker Chambers IV, 11th Floor, Nariman Point, Mumbai - 400021 Tel.: +91 22 43347000 Fax: + 91 22 43347002 E-mail: secretary@transchem.net Website: www.transchem.net (India) Limited SUNITA BONDS & HOLDINGS LTD. Regd off: 408, Princep Street, Kolkata, West Bengal, lncfia, 700072 Corp Off: 324A, Third Floor, Agarwal Plaa, Sec-14, Rohini, Oelhl-110085 Extracts of the Standalone Unaudited Financial Results For the Quarter and Half year ended September30, 2026 Partku&&tt 2. ~etPmrn, {Lou}~ lhll i!cmd{tfflff. Tu, 0,49 7.5'! 13.45 �������������� e....-ons, ano,·« ErnG«1-- (l:!m$\ �� Total COfllpfehensl\,e IJ'loomet(Loss) fot the s. Tola! ComJl(etienr.>;e income ltt Ille pe(iod 0.-19' 5.36 penod (ComprlsP'lt, Proftt/(Loss) for Ule pec,od !~ ng Proft I (lli$$J lo, 1ho P61!°'1 (allur � ������������������������� ���������� o:mlSI\H'9 -,n:1 diS(;Onlim111d cper;s!ion,l • Note: the Stoek Ex.r.tianges ,.moor Regulation 33 of Che SE81 (UsUn9 Obtig3Uon, a.-id OlsCI0$1,1re :stock E)(cha,19e(s) (YIWH.cso,inclia.com) and c~,w.~ 1n). ��������������� ���� 2.. ThO at,o,.,e 1ewll have been rovie-Ntd by ltlc ~VIM oommitloe aild apptQ'iOCI lr/ !tic Board ~l ������������ ������������������ ��������������������� Ind-AS} as prosc:ribOO ul\der scelioo 133 ol tho Companies Att ,2013 road wilh IND -AS rules i Al. amended) Fo, and on behaH of the Board of Directors of Ru bicon" Rohlt Mittal Date: 05.11.202& (Man~ ln9 0iloci0f't INNOVATION I DUALITY I CARE a MANGALAM DRUGS & ORGANICS LIMITED. Rubicon Research Limited Reg. Office: Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near G.P.O, Mumbai· 400001. ClN:l24230MH1972PLC116413 CIN: L73100MH1999PLC119744 Tel Ph No. 91-22-22616200 Fax No. 91·22-22619090 Email Id: conlacius@mangaJamdl\lgs.comWebsite:http://www.mangalamdrugs.com Regd. Office: Plot No. B-75, MedOne House, (A} EXTRACT OF §TANOALONE ANO CON§OLJOATEO UN-AUDITED FINANCIAL RE§ULT§ FOR THE Road No. 33 Wagle Estate, QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2026 (Rs. in Lakhs) Thane West. Maharashtra, India, 400604 Standalone Consolidated E-mall: jrwestors@rubicon.co.in Sr. Quarter Ended Half Year Ended Year Ended Quarter Ended Half Year Ended Year Ended Website: www.rubicon.co.in Particulars No. 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 30.09.2026 30.06.2026 30.09.2025 30.09.2026 30.09.2025 31.03.2026 Tel: +91 22 61414 000 (Unaudit&d) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audi1ed) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) UNAUDITED STANDALONE AND CONSOLIDATED t. T<Mal Income fiohl Operations (net) 7.956.06 5,723.10 4,967.19 13,679.16 10,692.10 23,289.58 7,956.06 5,723.10 4,957.19 13,679.16 10,692.10 23,289.58 2. r-iLiltt/ n u:.s)ald other income, finanoecosts but before exuruGonal items t899.21) (660.u:iu 11,2~.681 (1.565.~• {2,529.481 {4,790.74) (899.09) (674.611 11.,...,.611 {1,57~.70J (2,546.50) {4,857.14) FINANCIAL RESULTS FOR THE QUARTER AND 3 ProfiV(ll>ss) from O<llff\alY actMlles before lax (899.21) (666.09) (1,236.68) (1,565.30) (2,529.48) (4,798.74) (899.09) (674.61) (1.24&.&n (1,573.70) (2,546.50) (4,857.14) HALF YEAR ENDED SEPTEMBER 30, 2026 4 Net nouu(loss) for thep eriod aJte< tax(aner Exceptional ano /or ... In compliance with Regulation 33 of the SEBI (Listing Ex.iraordinary items (720.93) (755.36) .{7. 24.64) (1.476.29) (2,097.44} (4,381.42) (720.81) {763.88) (734.63) (1,484.69) (2,114.46) {4,440.00) •• 1otA, .,omprenenswe 1rl(ome t1->.1,uol ,, ,,. ... , l IL, fLJ,'"'f} ,., {IJ•.••• \t tO,U'fl 11 ..l l',L lt {l, ) l', l<tU,<tUI \•. Obligations and Disclosure Requirements) Regulations, • • 1-'aid,up tqu1ty = ldre l,;apital (t-ace value 01 t<s 11.h'• pel share) 1::mL,OL 15oL.OL 1 1.'.JOL.DL 1ao£.8l 15oL.OL 150£.0L 1 15o,.82 15i:u'..lS2 1:mL,0£ 1 . 2015 ("SEBI Listing Regulations"), the Board of 7 Reserve exauo,ng Revaklatioo Reveres as per balance sh~1 of Directors of the Rubicon Research Limited ("Company") . . . . . previous aocx:wUng year 8,749.38 8,723.08 at its meeting held on Thursday, November 05. 2026, 8. Earnings Per Share (EP,1 (ol"" 10/-each ool annua ised): , ,,, approved the Unaudited Standalone and Consolidated 8) o.s.:.t<; l<J,.A.>} , ...J oJ '"·=• 'fJ,.t;;)) Ill,=• 1•.JJO '"·"" t•-~, '"·=• \ l.;l,JUI OLO,UJO b) Diluted (4.551 (4.77) (4.58) (9.33) (13.25) (27.681 (4.55) (4.83) (4.641 (9.38) (13.361 (28.05) Financial Results For lhe quarter and half year ended September 30, 2026 ( .. Financial Results"). Nole 1) The abo,-e Is an exllal:t ol thed etaiJOO formal of Unaudied Standalone and Consolidated financial ResullS lor lhe Quarter & Haff year ended 301)) Seplember, 2026 filed with the Siock Exct>ange unoor Regulation 33 ofthe SE61( Lisling bligations and Disclo5'Jre The Financial Results. along with the Limited Requiremenls) Regulations 2015. The full format of the Financial Resu!1s f01 tho Quarter &y ear ended30th Sep:omber. 2026 is-availableo n the Stock Exchange websites &{he Company's websile.( VI\Wt.bseindia.comand www.nsemdia.coma ndw Nw.mangalamdrugs.com). Review Report issued by Mis. Deloitte Haskins . & Sells LLP, Statutory Auditors of the Company, For & on Behalf of the Board are available on the website of the Company at Mangalam Drugs & Organics limited GOVARDHAN M.DHOOT hllps;//www, rubicon .co. in /inyes tors/fina ncial-reporls Plac,, : Mumbai . CHAIRMAN & MANAGING DIRECTOR and on websites of the Stock Exchanges i.e. Date : 05.11.2026 • DIN: 01240086 BSE limited and National Slock Exchange www,bseindja.com of India Limited at and www.nseindia.com respectively. In compliance with For Rubicon Research Limited Sd/· Place: Thane Company Secretary $Sitfol.zJa ENGINEERS ~fs.zJI lcUifl~s ;EIL INDIA LIMITED �������� ~~ ilf¾<ll\"lllf COMPANY SECRETARIAT 8-"'' ELIN ELECTRONICS LIMITED CIN: L29304DL1982PLC428372 Corporale & Regfstered Office: 4771, Bharat Ram Road, 23, Daryaganf, New Delhi - 110 002, India Tel.: 011·43000400 E·mail: rkc@ellnindia.com Website: www.elinindia.com THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 STAND.ALONE . CONSOLIDATEO No. Particulars 30.09.2026; 30.06.20261 30.09.2025; 30.09.2026 30.09.2025: 31.03.2026:3 0.09.2026;3 0.06.2026; 30.09.2025 30.09.2026j 30.09.2025 31.03.2026 �������������� ������� ������� �������������� ������� �������������� j 1 1 2 Net Profit / (Lossl for the period (before Tax, Exceptional and/or Extraordinary Items & Share of proliV\loss) of Associates) 18.17 (17.70) 122.29 0.47 241.56 268.61 38.10 137.61) 138.66 0.49 265.33 305.62 4 Net Profit/ (Lossl for the period after tax (after Exceptional and/or Extraordinary Items &S hare of pro [Showing first 8,000 characters — download PDF for full document]